Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06205979
Status:
RECRUITING
Last Update Posted:
2024-01-16
First Post:
2024-01-03
Brief Title:
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diabetic retinopathy DR is considered the main etiology of blindness among working-age adults and Diabetic macular edema DME is the main reason for vision loss related to DR Retinal oedema is responsible for retinal micro-structural alterations retinal atrophy of photoreceptors and ganglion cell disorders In addition it might be considered consensual that the best improvements in VA could be accomplished when retinal oedema is managed In the context of a chronic and progressive disease DME has to be faced as a state to control as effectively and rapidly as possible Vascular endothelial growth factor VEGF is a protein that promotes the growth of new blood vessels It also makes the blood vessels more leaky Anti- VEGF medicines stop the growth of these new blood vessels This prevents damage to the retinal light receptors and loss of central vision The DME treatment has been shifted from the laser photocoagulation to anti-VEGF therapy The advantages of anti-VEGF therapy in decreasing DME and improving patients vision have been reported in many studies Ranibizumab in addition to aflibercept have been reported as the first line therapies among the other anti-VEGF There are several data demonstrating the efficiency of ranibizumab in treatment of patients with DME On the other hand there are studies that revealed poor response of some patients to anti-VEGF therapies even after 3 or more injections Non-modifiable risk factors for diabetic retinopathy are gender and DM duration
Modifiable risk factors contributing to the development of diabetic retinopathy are elevated blood sugar levels blood pressure and dyslipidemia which is the imbalance of lipids such as cholesterol low-density lipoprotein cholesterol LDL-C triglycerides and high-density lipoprotein HDL This condition can result from diet tobacco exposure or genetic Hard exudates are thought to be induced by the leakage of lipids from dysfunctional retinal capillaries Therefore theses were formulated that higher levels of total cholesterol LDL-C and triglycerides could be considered biomarkers of the development of hard exudates in DM patients Aim of the work
- Correlate between dyslipidemia and the response of patients with diabetic macular oedema to intravitreal anti-VEGF injection
Modifiable risk factors contributing to the development of diabetic retinopathy are elevated blood sugar levels blood pressure and dyslipidemia which is the imbalance of lipids such as cholesterol low-density lipoprotein cholesterol LDL-C triglycerides and high-density lipoprotein HDL This condition can result from diet tobacco exposure or genetic Hard exudates are thought to be induced by the leakage of lipids from dysfunctional retinal capillaries Therefore theses were formulated that higher levels of total cholesterol LDL-C and triglycerides could be considered biomarkers of the development of hard exudates in DM patients Aim of the work
- Correlate between dyslipidemia and the response of patients with diabetic macular oedema to intravitreal anti-VEGF injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None